

(Rs. in Crores except per share data)


Statement of Standalone Audited Financial Results for the Quarter Ended 30-Jun-2019

Particulars	Quarter ended			Year ended
	30-Jun-2019	31-Mar-2019	30-Jun-2018	31-Mar-2019
Revenue				
Net sales	1566	1319	1415	5557
Other operating income	37	38	37	205
Revenue from operations (net)	1603	1357	1452	5762
Other income	31	227	34	382
Total revenue	1634	1584	1486	6144
Expenses				
Cost of materials consumed	366	341	310	1207
Purchases of stock-in-trade	69	88	92	343
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(16)	(23)	(4)	(5)
Employee benefits expense	280	256	252	1014
Finance costs	117	119	117	481
Depreciation and amortisation expense	149	147	141	579
Other expenses	392	401	390	1590
Total expenses	1357	1329	1298	5209
Profit before tax	277	255	188	935
Tax expense				
Current Tax	60	57	41	194
Deferred Tax	(6)	34	25	(4)
Total tax expense	54	91	66	190
Net profit for the period	223	164	122	745
Other comprehensive income				
Items that will not be reclassified to profit or loss	(3)	2	(1)	(8)
Income tax relating to items that will not be reclassified to profit or loss	1	0	-	3
Items that will be reclassified to profit or loss	9	59	(71)	43
Income tax relating to items that will be reclassified to profit or loss	(3)	(21)	25	(15)
Total other comprehensive income	4	40	(47)	23
Total comprehensive income	227	204	75	768
Paid-up equity share capital (Face value of Rs. 5 each)	84.62	84.62	84.62	84.62
Other Equity excluding Revaluation Reserves				4930
Earnings per share (of Rs. 5/- each) (not annualised for the quarter):				
Basic	13.18	9.73	7.21	44.05
Diluted	13.18	9.73	7.21	44.05

Notes:

- 1 The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 23-Jul-2019. The auditor have carried out an audit of the above said results. There is no qualification in the auditor's report on this statement of financial results.
- 2 The Company operates in a single segment i.e Generic Formulation Business.
- 3 The figures for the quarter ended 31-Mar-2019 is the balancing figure between audited figures in respect of the full financial year and for the period upto the end of the third quarter of relevant financial year.
- 4 The listed non-convertible debentures of the company aggregating Rs. 1874 crores as on 30-Jun-2019 (previous year ended Rs. 1957 crores) are secured by way of first pari passu charge created through mortgage on certain specified immovable & movable assets and hypothecation of identified trademarks of the Company and the asset cover thereof exceeds hundred percent of the principal amount of the said debentures.
- 5 Effective 01-Apr-2019, the Company has adopted Ind AS 116 Leases using modified retrospective approach. This has resulted in recognizing right of use assets and lease liability as on 01-Apr-2019. The adoption of the standard did not have any material impact to the financial results.
- 6 The figures for the corresponding previous period have been restated/regrouped wherever necessary, to make them comparable.

For TORRENT PHARMACEUTICALS LIMITED



SAMIR MEHTA
Executive Chairman

Place : Ahmedabad, Gujarat

Date : 23-Jul-2019

